On the morning of September 24, the First Affiliated Hospital of Xi’an Jiaotong University (XJTU) held a strategic cooperation seminar for clinical research with Janssen (China) R&D of Johnson & Johnson Group. Dr. Li Zili, Vice President of Global Drug Development in Janssen Pharmaceuticals of Johnson & Johnson Group and Head of Asia-Pacific R&D, Dr. Jiao Qing 'an, Head of Clinical Research Operation Department of Janssen (China) R&D, Dr. Zheng Yi, Head of Asia-Pacific Center of Excellence in Translational Science of Janssen (China) R&D, and heads of R&D in different fields of Janssen (China) R&D, President Shi Bingyin of our hospital, Lu Mingying, Director of Clinical Pharmacological Institution, Directors of Department of Hematology, Department of Urology, Department of Oncology, Department of Orthopedics and Clinical Research Center, Professor Fan Fenling from Department of Structural Heart Diseases, Xiong Ying from Department of Cardiology and all staff from relevant institutions and offices attended the seminar. The seminar was co-chaired by Lu Mingying, Director of Clinical Pharmacological Institution and Dr. Shao Ning, Head of Clinical Research Operation Department of Janssen (China) R&D.
First, President Shi Bingyin introduced the basic information of our hospital. Subsequently, Director Lu Mingying introduced the development history of clinical drug trial institutions in our hospital and the general situation of the implementation and standardized management of clinical trials. Dr. Li Zili, Vice President of Global Drug Development in Janssen Pharmaceuticals of Johnson & Johnson Group and Head of Asia-Pacific R&D, introduced the R&D situation of Johnson & Johnson Group and Janssen (China) R&D covering the company's R&D strategy, therapeutic areas and research direction of Janssen (China) R&D, recently-approved new drugs, R&D layout and previous cooperation projects between Janssen (China) R&D and our hospital.
After explicit introduction, bilateral sides discussed how to explore more cooperation opportunities in varying areas, such as clinical research and talent training,etc.
Subsequently, Dr. Li Zili stressed that Janssen (China) R&D is gradually diverting its R&D strategy towards the western region and Janssen (China) R&D has an innovative medicine incubation base. He hoped to cooperate with our hospital in the field of basic research transformation, and will also initiate more cooperation projects. Finally, President Shi Bingyin concluded the seminar. Through this seminar, bilateral sides expected further in-depth cooperation in terms of clinical trials, R&D and incubation of new drugs. Our hospital has a high-level research team and platform. There is a huge market potentialand broad prospect for cooperation in western region and even China. Both sides hope that bilateral cooperation can make modest contribution for the development of health and medicine in China and the world.
